13 June, 2017
Amgen Inc. has $218 highest and $160 lowest target. The company now has a consensus rating of "Hold" and an average price target of $6.33.
Several analysts recently issued reports on the stock. The firm has "Buy" rating by Zacks given on Tuesday, August 25. As per Friday, July 31, the company rating was maintained by RBC Capital Markets. On Wednesday, May 4 the stock rating was downgraded by Evercore to "Hold". On Friday, July 31 the stock rating was maintained by Deutsche Bank with "Buy".
Investors may be interested in viewing the Gross Margin score on shares of Agenus Inc. The stock had a trading volume of 404,853 shares. The FCF Score of Agenus Inc. About 195,415 shares traded. It has underperformed by 18.96% the S&P500.The move comes after 8 months negative chart setup for the $312.64 million company.
Amgen Inc.is a biotechnology company. The company has market cap of $121.64 billion. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer.
Analysts await Amgen, Inc. AMGN's profit will be $2.28B for 13.32 P/E if the $3.09 EPS becomes a reality. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.14.
Since February 14, 2017, it had 2 insider purchases, and 0 sales for $60.33 million activity. (NasdaqCM:AGEN) is -1.436908. The Return on Invested Capital is a ratio that determines whether a company is profitable or not. Its down 0.17, from 1.26 in 2016Q3. It dived, as 98 investors sold Amgen, Inc. shares while 488 reduced holdings. 111 funds opened positions while 527 raised stakes. The same analysts are predicting that the company shares will trade to $7.95 within the next 12-18 months. Biondo Investment Advisors Limited Liability Corporation owns 0.3% invested in Amgen, Inc. (NASDAQ:AMGN) for 6,130 shares. Geode Cap Lc stated it has 0% in Agenus Inc (NASDAQ:AGEN). Kistler has invested 0% in Agenus Inc (NASDAQ:AGEN). Artal Group, Luxembourg-based fund reported 2.00 million shares. Pacad Invest owns 200 shares or 0% of their United States portfolio. (NASDAQ:AMGN). Moreover, First City Capital has 0.44% invested in Amgen, Inc. The shares were bought at an average price of $3.35 per share, for a total transaction of $335,000.00. Nomura Asset Mgmt holds 0.02% of its portfolio in Quintiles IMS Holdings Inc (NYSE:Q) for 17,200 shares. Qvt Fincl Lp accumulated 0.51% or 4.10M shares. M&T Commercial Bank holds 0.02% or 46,261 shares. (NASDAQ:AMGN) or 203,582 shares. Connecticut-based Columbus Circle Invsts has invested 0.04% in Amgen, Inc. Wall Street is only getting more bullish on the stock, with 4 of analysts who cover AGEN having a buy-equivalent rating. Therefore 80% are positive. The firm has "Buy" rating by Maxim Group given on Friday, March 11. As per Monday, March 28, the company rating was downgraded by SunTrust. MLV maintained Agenus Inc (NASDAQ:AGEN) rating on Monday, July 27. The rating was initiated by Jefferies with "Buy" on Wednesday, December 16. Three analysts have made estimates for Agenus' earnings, with the lowest sales estimate coming in at $2.9 million and the highest estimate coming in at $6.66 million.
"Chairman & CEO at Agenus Inc., ARMEN GARO H on 2017-04-12 Buy 100000 shares of the company at a price of $3.35". Shares for $60.00M were bought by INCYTE CORP.
Investors sentiment increased to 1.75 in 2016 Q4.
Agenus (NASDAQ:AGEN) last announced its quarterly earnings data on Thursday, May 4th. The share price has moved forward from its 20 days moving average, trading at a distance of 0.96% and stays -0.78% away from its 50 days moving average. Credit Suisse Ag reported 0.01% stake. We have $3.20 PT which if reached, will make NASDAQ:AGEN worth $21.88 million less. Similarly, investors look up the share price over 12 month periods. It was reported on Jun, 13 by Barchart.com. Crestwood Advisors Llc stated it has 32,928 shares. Leonard Green Prtnrs LP reported 55.92% stake.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.